2024年5月23日 · XDR-TB, an abbreviation for extensively drug-resistant tuberculosis (TB), is a form of TB that is caused by a strain of M. tuberculosis complex that is resistant to rifampicin (and may also be resistant to isoniazid), and that is also resistant to at least one fluoroquinolone (levofloxacin or moxifloxacin) and to at least one other Group A drug ...

Extensively drug-resistant tuberculosis (XDR-TB) is a form of tuberculosis caused by bacteria that are resistant to some of the most effective anti-TB drugs. XDR-TB strains have arisen after the mismanagement of individuals with multidrug-resistant TB (MDR-TB).

xdr-tb是广泛耐药结核病的缩写。 它是一种由结核分枝杆菌复合群菌株引起的结核病，该菌株对利福平耐药（也可能对异烟肼有耐药性），并且对至少一种氟喹诺酮类药物（左氧氟沙星或莫西沙星）和至少一种其他A类药物（贝达喹啉或利奈唑胺）耐药。

2023年12月21日 · Multidrug-resistant TB disease (MDR TB) is caused by germs that are resistant to two or more of the main TB medicines: isoniazid and rifampin. Two more serious forms of MDR TB are called pre-extensively drug-resistant TB (pre-XDR TB) …

2021年1月27日 · The definition of extensively drug-resistant tuberculosis (XDR-TB) has been revised by the World Health Organization (WHO)’s Global TB Programme, who have also defined pre-XDR-TB for the first time, highlighting the seriousness of these forms of TB.

2006年12月在南非等国家发现了广泛耐药结核病（extensively drug-resistanttuberculosis，XDR-TB）患者，其临床疗效差，病死率高。 鉴于此，WHO宣布其对全球公共卫生健康构成了严重的威胁，并于2008年紧急更新了"耐药结核病规划管理指南" [6]，为全球控制耐药结核病尤其是XDR-TB提供了最新的指导和建议。

广泛耐药结核（Extensively drug-resistant tuberculosis，即XDR-TB）是结核病的一种，专指对利福平（rifampicin）和异烟肼（isoniazid）具抗药性（对这些一线治疗结核药物具有抗药性的结核称作“多药抗药性结核”——MDR-TB），且对全部喹诺酮（quinolone）类药物以及至少对 ...

泛耐药结核/广泛耐药肺结核(XDR-TB,Extensive Drug Resistant TB or Extreme Drug Resistance) 耐多药结核描述至少对两种主要一线抗结核药物 - 异烟肼和利福平具耐药性的结核杆菌菌株。

2025年1月6日 · Extensively drug-resistant TB (XDR TB) is a rare type of MDR TB caused by TB bacteria that are resistant to: Isoniazid and rifampin, a fluoroquinolone, and a second-line injectable (amikacin, capreomycin, and kanamycin) or

This chapter provides guidance on the strategies for the treatment of multidrug- and extensively drug-resistant TB (M/XDR-TB), with emphasis on regimen design. The treatment of mono- and poly-drug-resistant TB is addressed in Chapter 6.